Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy.
P atients with heart failure due to nonischemic cardiomyopathy are at an increased risk for sudden cardiac death (SCD). In the mid-2000s, 2 randomized clinical trials provided helpful data on the benefit of implantable cardioverter defibrillators (ICDs) for primary prevention of SCD (hereafter referred to as primary prevention ICDs) in these patients. 1, 2 The
Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial 1 showed a significant reduction in the risk for SCD with use of primary prevention ICDs in patients with a left ventricular ejection fraction of 35% or less owing to nonischemic cardiomyopathy and premature ventricular complexes or nonsustained ventricular tachycardia. A trend toward reduced all-cause mortality was seen with use of an ICD. 1 The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) 2 showed a significant improvement in the survival of patients with New York Heart Association (NYHA) class II or III heart failure symptoms due to ischemic or nonischemic cardiomyopathy with use of a primary prevention ICD. Data from these trials led to the designation of the primary prevention ICD as a class I therapy in patients with NYHA class II or III heart failure symptoms due to nonischemic cardiomyopathy. 3 The recently published Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality (DANISH trial) 4 enrolled patients with NYHA class II or III heart failure symptoms (or NYHA class IV symptoms if cardiac resynchronization therapy [CRT] was planned) with a left ventricular ejection fraction of 35% or less owing to nonischemic cardiomyopathy and an increased level of N-terminal pro-brain natriuretic peptide (NT-proBNP) despite guideline-directed medical therapy. The DANISH trial showed a reduction in SCD but not in all-cause mortality with use of an ICD. 4 To better understand the effect of primary prevention ICDs on survival among patients with nonischemic cardiomyopathy, we conducted a meta-analysis of randomized clinical trials on this topic.
Methods
Selection criteria included a randomized clinical trial design with ICD vs medical therapy as the comparators and a follow-up of at least 12 months. Studies had to have at least 100 patients and to have been published in English from January 1, 2000, through October 31, 2016. We excluded trials of CRT and those that compared the ICD with an antiarrhythmic medication, including amiodarone. Studies that enrolled patients with ischemic and nonischemic cardiomyopathy were included if data on patients with nonischemic cardiomyopathy were reported separately or could be obtained directly from the study investigators. Studies that included an ICD arm, a medical therapy arm, and other comparators were included if data on the ICD and medical therapy arms were reported separately. We searched PubMed using the following search terms: implantable defibrillator OR implantable cardioverter defibrillator AND nonischemic cardiomyopathy. This search yielded 10 studies, of which only 1 (the DEFINITE trial) met our criteria (2 studies included CRT only, 1 compared ICD with amiodarone only, and 6 were substudies of the DEFINITE trial). A search of bibliographies of pertinent articles and queries of experts in this field resulted in 3 additional studies: the Cardiomyopathy Trial (CAT), 5 the SCD-HeFT (ICD and medical therapy groups of patients with nonischemic cardiomyopathy), 2 and the DANISH trial (patients with an ICD and medical therapy without CRT) 4 ( Figure 1) . We used the Cochran Q test to examine heterogeneity among the included trials. P < .05 indicated statistical significance.
Results
The 4 randomized clinical trials that met our selection criteria included 1874 unique patients with 937 in the ICD group and 937 in the medical therapy (control) group. Mortality rates are provided in the Table. Pooling data with fixed-and random-effects models from these 4 studies showed a significant reduction in allcause mortality with use of an ICD (hazard ratio, 0.75; 95% CI, 0.61-0.93; P = .008; P = .87 for heterogeneity) ( Figure 2 ). We performed 2 sensitivity analyses. One excluded the CAT, which was smaller and had a shorter follow-up than the other 3 trials, and the other excluded the DANISH trial, given the time difference between the completion of that trial relative to the other 3 trials. The results did not change appreciably. To further address the issue of the time difference among the trials, we conducted a meta-regression that accounted for each trial's year of publication in the metaanalysis. We found no evidence that time was a modifier of the relationship between use of an ICD and all-cause mortality (P = .53).
Discussion
We showed a significant survival benefit of use of an ICD in patients with nonischemic cardiomyopathy. Our findings are consistent with the results of the DEFINITE 1 and SCD-HeFT 2 trials.
Compared with these 2 trials, the DANISH trial 4 differed in a number of ways. First, 58% of patients in the ICD and the control groups in the DANISH trial received a CRT device. Therefore, data from the overall DANISH trial should not be extrapolated to patients with nonischemic cardiomyopathy who are eligible for an ICD but not for CRT. The frequent use of CRT likely contributed to the lower than projected mortality rate in both groups in the DANISH trial. Second, medical therapy in both groups in the DANISH trial was superior to that used in clinical practice. 4, 6 Third, the DANISH trial is the only trial to date to require an elevated NT pro-BNP level for a patient to qualify for enrollment, and the median level of NT pro-BNP of enrolled patients was 1244 pg/mL in the ICD group and 1110 pg/mL in the medical therapy group (to convert NT pro-BNP to nanograms per liter, multiply by 1.0). 4 This finding, along with the older age of patients in the DANISH trial (mean age, 64 years compared with 52-60 years in the other 3 trials), may have led to the inclusion of patients who are more likely to die of non-SCD causes. More granular data on the mode of death from the DANISH trial would be important. Finally, the high use of CRT and guideline-directed medical therapy in the DANISH trial likely reduced their statistical power for showing a significant difference in the primary outcome, despite extending the follow-up period to more than 67 months.
Strengths and Limitations
Another meta-analysis of primary prevention ICDs in patients with nonischemic cardiomyopathy was recently published. 7 Compared with that analysis, our approach was more robust at reducing heterogeneity because we included only trials that compared the ICD with optimal medical therapy and excluded trials of CRT and antiarrhythmic medications. Furthermore, through our access to patient-level data in the DEFINITE 1 and SCD-HeFT 2 trials, we were able to provide actual mortality rates from all the trials (Table) . However, a limitation of our meta-analysis is noteworthy. Although we used patient-level data from the SCD-HeFT 2 and the DEFINITE trials, 1 we had no access to patient-level data in the CAT 5 or the DANISH trial. 
